tremfya
janssen-cilag international nv - guselkumab - psoriazė - imunosupresantai - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
brexin
chiesi pharmaceuticals gmbh - piroksikamas - milteliai geriamajam tirpalui - 20 mg - piroxicam
co-diovan
sia novartis baltics - valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 160 mg/12,5 mg; 80 mg/12,5 mg; 160 mg/25 mg - valsartan and diuretics
dexketoprofen kalceks
as kalceks - deksketoprofenas - injekcinis ar infuzinis tirpalas - 50 mg/2 ml - dexketoprofen
dicloberl
berlin-chemie ag (menarini group) - diklofenako natrio druska - žvakutės - 75 mg/3 ml; 50 mg; 100 mg - diclofenac
diclofenac-ratiopharm uno
ratiopharm gmbh - diklofenako natrio druska - modifikuoto atpalaidavimo tabletės - 100 mg; 75 mg/2 ml; 150 mg - diclofenac
dicuno
vitabalans oy - diklofenako kalio druska - plėvele dengtos tabletės - 25 mg; 50 mg - diclofenac
fastum
a.menarini industrie farmaceutiche riunite s.r.l. - ketoprofenas - gelis - 25 mg/g - ketoprofen
feloran
actavis nordic a/s - diklofenakas - gelis - 10 mg/g - diclofenac
feneit
sia ingen pharma - deksketoprofenas - plėvele dengtos tabletės - 25 mg - dexketoprofen